DEF 14A: Hoth Therapeutics Seeks Shareholder Approval for Equity Incentive Plan Amendment at Upcoming Annual Meeting

Sentiment:

Definitive Proxy Statement 18 June 2024 6:07 AM

Hoth Therapeutics is holding its annual shareholder meeting on August 7, 2024, to vote on director elections, ratify the appointment of its accounting firm, and approve an amendment to its equity incentive plan.

Summary

Hoth Therapeutics will hold its 2024 Annual Meeting of Shareholders virtually on August 7, 2024.
Shareholders will vote on three proposals: electing directors, ratifying the appointment of WithumSmith+Brown, PC as the independent accounting firm, and approving an amendment to the 2022 Omnibus Equity Incentive Plan.
The proposed amendment to the equity incentive plan would increase the number of shares reserved for issuance by 500,000, from 591,317 to 1,091,317 shares.
The Board of Directors unanimously recommends voting FOR all proposals.
The record date for determining shareholders eligible to vote is June 14, 2024.
Shareholders can vote online, by mail, or by phone.
The company is using notice and access to deliver proxy materials, reducing paper and mailing costs.

Sentiment

Score: 6

Explanation: The document is primarily informational, outlining the proposals for the annual meeting. The sentiment is neutral, with a slight positive leaning due to the Board's recommendations and the company's efforts to reduce costs.

Positives

The company is taking steps to reduce costs by providing proxy materials online.
The Board of Directors has determined that a majority of the Board consists of members who are currently independent.
The company has adopted a Code of Business Conduct and Ethics which applies to all of its officers, directors and employees and charters for its audit committee, its compensation committee and its nominating and corporate governance committee.
The company has a formal policy regarding approval of transactions with related parties.

Negatives

The company is seeking to increase the number of shares available under its equity incentive plan, which could dilute existing shareholders' ownership.
The company paid bonuses to named executive officers in 2023, despite not having specific performance targets outlined in the document.
The company has had related party transactions with Armistice Capital Master Fund Ltd.

Risks

Failure to approve the amendment to the equity incentive plan could limit the company's ability to attract and retain talent.
The company's reliance on equity-based compensation could lead to dilution of existing shareholders' ownership.
The company's future performance is subject to various risks, including those related to the competitive medical devices marketplace.

Future Outlook

The company anticipates that the additional shares requested under the amendment, plus the remaining shares that are available for issuance under the 2022 Plan, to be sufficient for a period of one year.

Management Comments

The Board believes that the combined role of Chairman and Chief Executive Officer strengthens the communication between the Board and management.
The Board believes that Mr. Knie is best situated to serve as Chairman because he is the director most familiar with the Company's business and industry and is also the person most capable of effectively identifying strategic priorities and leading the discussion and execution of corporate strategy.

Industry Context

The document does not provide specific details on how this announcement relates to broader industry trends or competitors beyond mentioning the competitive medical devices marketplace.

Comparison to Industry Standards

The document does not provide specific details on how the results compare to global benchmarks or comparable companies.
The document mentions that the Board and Compensation Committee worked with management to evaluate a number of factors, and carefully considered (i) the potential dilutive impact on shareholders, (ii) our historical run rate and overhang, (iii) the number of shares remaining available for issuance, (iv) forecasted grants, (v) the realities of equity awards being a key component of designing competitive compensation packages necessary for attracting and retaining key talent in a competitive medical devices marketplace, (vi) our strategic growth plans, and (vii) the interests of our shareholders.

Related Party Transactions

On September 13, 2023, we entered into a securities purchase agreement with certain investors, including Armistice Capital Master Fund Ltd.
On December 29, 2022, we entered into a securities purchase agreement with Armistice pursuant to which we agreed to sell an aggregate of (i) 140,000 shares (the Shares) of common stock, (ii) pre-funded warrants to purchase up to 1,860,000 shares (the Pre-Funded Warrant Shares) of common stock and (iii) warrants (the January 2023 Warrants) to purchase up to 2,500,000 shares (the Warrant Shares and together with the Shares and the Pre-Funded Warrant Shares, the Registrable Securities) of common stock at a purchase price of $5.00 per share and accompanying warrant (less $0.001 for each pre-funded warrant and accompanying warrant) in a private placement for aggregate gross proceeds of approximately $10 million, exclusive of placement agent commission and fees and other offering expenses.
On March 27, 2024, we entered into an inducement offer agreement with Armistice to immediately exercise, for cash, all of the January 2023 Warrants at a reduced exercise price of $1.6775 per share for gross proceeds to us of approximately $4.2 million before deducting placement agent fees and other offering expenses payable by us.

Stakeholder Impact

Shareholders will be impacted by the decisions made at the Annual Meeting, particularly regarding the equity incentive plan.
Employees and non-employee directors may be impacted by the approval of the amendment to the equity incentive plan, as it affects their potential compensation.
The company's performance and strategic decisions will ultimately impact all stakeholders, including customers, suppliers, and creditors.

Next Steps

Shareholders should review the proxy materials and vote on the proposals.
The company will hold the Annual Meeting on August 7, 2024.
The company will file a Current Report on Form 8-K with the SEC to disclose the final voting results within four business days after the Annual Meeting.

Key Dates

Date	Description
May 4, 2018	The Companys Board of Directors adopted the Hoth Therapeutics, Inc. 2018 Omnibus Equity Incentive Plan (the 2018 Plan).
February 2018	Withum was appointed to serve as our independent registered public accounting firm.
March 24, 2022	The Companys Board of Directors adopted the Hoth Therapeutics, Inc. 2022 Omnibus Equity Incentive Plan (the Prior 2022 Plan).
June 23, 2022	The Prior 2022 Plan became effective upon approval of the Prior 2022 Plan by the Companys shareholders at the Companys annual meeting of shareholders.
December 29, 2022	We entered into a securities purchase agreement with Armistice pursuant to which we agreed to sell an aggregate of (i) 140,000 shares (the Shares) of common stock, (ii) pre-funded warrants to purchase up to 1,860,000 shares (the Pre-Funded Warrant Shares) of common stock and (iii) warrants (the January 2023 Warrants) to purchase up to 2,500,000 shares (the Warrant Shares and together with the Shares and the Pre-Funded Warrant Shares, the Registrable Securities) of common stock at a purchase price of $5.00 per share and accompanying warrant (less $0.001 for each pre-funded warrant and accompanying warrant) in a private placement for aggregate gross proceeds of approximately $10 million, exclusive of placement agent commission and fees and other offering expenses.
January 3, 2023	The closing of the offering occurred.
March 28, 2023	We entered into an employment agreement (the 2023 Knie Employment Agreement) with Robb Knie, pursuant to which Mr. Knie continues to serve as our Chief Executive Officer.
June 2, 2023	The Companys Board approved the 2022 Plan, which included increasing the number of shares of common stock by 495,317 shares such that a total of 591,317 shares of common stock were reserved for issuance under the 2022 Plan.
July 17, 2023	Jeff Pavell, David Sarnoff, Graig Springer, and Wayne Linsley were each granted ten-year options to purchase up to 7,500 shares of the Companys common stock at an exercise price of $2.59, which options vested in full upon grant.
August 18, 2023	The 2022 Plan was approved by shareholders.
September 13, 2023	We entered into a securities purchase agreement with certain investors, including Armistice Capital Master Fund Ltd.
September 15, 2023	The closing of the offering occurred pursuant to which we received gross proceeds of $2.89 million in the aggregate, prior to deducting placement agents fees and other offering expenses payable by us.
March 27, 2024	We entered into an inducement offer agreement with Armistice to immediately exercise, for cash, all of the January 2023 Warrants at a reduced exercise price of $1.6775 per share for gross proceeds to us of approximately $4.2 million before deducting placement agent fees and other offering expenses payable by us.
April 1, 2024	We issued 485,000 shares of common stock to Armistice upon exercise of the January 2023 Warrants and 2,015,000 shares of common stock are held in abeyance for future issuance.
May 15, 2024	Our Compensation Committee recommended and our Board approved an amendment to our 2022 Plan to increase the number of shares of common stock reserved for issuance thereunder from 591,317 shares to 1,091,317 shares, an increase of 500,000 shares.
June 14, 2024	Record date for the 2024 Annual Meeting.
June 17, 2024	Date of the notice of annual meeting of shareholders.
June 18, 2024	We will begin mailing a Notice of Internet Availability of Proxy Materials to all shareholders of record.
August 7, 2024	2024 Annual Meeting of Shareholders.
February 18, 2025	Deadline for shareholders to submit proposals for inclusion in the 2025 proxy materials.
April 9, 2025	Start date for shareholders to provide notice of proposals to be presented at the 2025 Annual Meeting without inclusion in proxy materials.
May 9, 2025	End date for shareholders to provide notice of proposals to be presented at the 2025 Annual Meeting without inclusion in proxy materials.
June 8, 2025	Deadline for shareholders to give timely notice under the universal proxy rules of an intent to solicit proxies in support of director nominees other than our nominees for the 2025 Annual Meeting.

Keywords

proxy statement, annual meeting, shareholders, directors, equity incentive plan, WithumSmith+Brown, compensation, corporate governance, Hoth Therapeutics

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.